PTC Therapeutics, Inc. (PTCT) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $75.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 17%; Below-average business quality.
PTC Therapeutics is a global biopharma commercializing rare disease therapies including Sephience (PKU, approved in US/EEA/Japan), Emflaza (DMD, US), Translarna (DMD, non-EEA markets), and Upstaza/Kebilidi (AADC deficiency). Emflaza faces growing generic competition following... Read more
Sell if holding. Engine safety override at $75.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 17%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — PTC Therapeutics, Inc.
Latest news
- NEWS PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Hu — Seeking Alpha positive
- NEWS PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Benzinga — Benzinga negative
- NEWS PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.5% - Here's What Happened - MarketBeat — MarketBeat negative
- NEWS M&T Bank Corp Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat — MarketBeat neutral
- NEWS Exploring analyst estimates for PTC Therapeutics (PTCT) Q1 earnings, beyond revenue and EPS - MSN — MSN neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductEmflaza10-K Item 1: 'we have seen an increase in competition from generics, which has, and we expect will continue to have, a negative impact on Emflaza net product revenue'
- HIGHProductTranslarna10-K Item 1A: 'There is a substantial risk that as a result of the EC's adoption of the CHMP's negative opinion we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA.'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWJessica Chutter appointed to the Board as a Class I director (term expiring at 2026 Annual Meeting), filling a vacancy. No officer departure. Routine board appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -22.6%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $75.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 17%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $69.88. Score 5.7/10, moderate confidence.
Take-profit target: $81.72 (+8.8% upside). Prior stop was $69.88. Stop-loss: $69.88.
Concentration risk — Product: Emflaza; Concentration risk — Product: Translarna; Quality below floor (3.4 < 4.0).
PTC Therapeutics, Inc. trades at a P/E of N/A (forward 27.0). TrendMatrix value score: 6.2/10. Verdict: Sell.
21 analysts cover PTCT with a consensus score of 4.0/5. Average price target: $94.
What does PTC Therapeutics, Inc. do?PTC Therapeutics is a global biopharma commercializing rare disease therapies including Sephience (PKU, approved in...
PTC Therapeutics is a global biopharma commercializing rare disease therapies including Sephience (PKU, approved in US/EEA/Japan), Emflaza (DMD, US), Translarna (DMD, non-EEA markets), and Upstaza/Kebilidi (AADC deficiency). Emflaza faces growing generic competition following orphan exclusivity expiry in February 2024, and Translarna has lost its EEA marketing authorization following a 2025 EC negative opinion.